Expression and its clinical significance of SHP2 in non-small cell lung cancer.
- Author:
Chunlan TANG
1
;
Xiangdong ZHOU
;
Heping YANG
;
Qinglian WANG
;
Rong ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; metabolism; pathology; Carcinoma, Non-Small-Cell Lung; metabolism; pathology; Carcinoma, Squamous Cell; metabolism; pathology; Female; Humans; Immunohistochemistry; Lung Neoplasms; metabolism; pathology; Lymphatic Metastasis; pathology; Male; Middle Aged; Protein Tyrosine Phosphatase, Non-Receptor Type 11; metabolism; Tissue Array Analysis
- From: Chinese Journal of Lung Cancer 2010;13(2):98-101
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND AND OBJECTIVEPrecious studies proven that aberrant tyrosine phosphorylation has linked with cancer. The aim of this work is to study the expression and significance of SHP2 in non-small cell lung cancer (NSCLC) through tissue microarray technique and immunohistochemical method.
METHODSEighty NSCLC specimens were constructed into tissue microarray and performed using immunohistochemistry.
RESULTSThe total positive rates of SHP2 were 70.7% (56/80) in NSCLC, 72.5% (29/40) in squamous cell carcinoma and 75% (27/40) in adenocarcinoma, which was not significant difference in sex, age, the size of tumor, histology, clinical stages and differentiation (P > 0.05), the positive rates of SHP2 were significantly higher in the cases with lymphnode metastasis than those without (P < 0.05).
CONCLUSIONThe expression rate of SHP2 is high and closely correlated to lymphnode metastasis in NSCLC, which implies the occurrence and development of lung cancer maybe related to SHP2, and SHP2 maybe a new marker and therapeutic targets for lung cancer.
